News >

Targeted Therapies Transform Outlook of FLT3- and IDH-Mutant AML

Caroline Seymour
Published: Wednesday, May 08, 2019

Lyndsey Runaas, MD

Lyndsey Runaas, MD

FLT3 and IDH1/2 mutations carry prognostic significance, and now therapeutic implications for patients with both newly diagnosed and relapsed/refractory acute myeloid leukemia (AML), explained Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication